1
00:00:00,000 --> 00:00:03,500
Tesamorelin is a growth hormone-releasing factor analog.

2
00:00:03,500 --> 00:00:10,167
Its US prescribing information addresses a specific clinical problem: excess abdominal fat in adults with

3
00:00:10,167 --> 00:00:13,667
HIV-associated lipodystrophy.

4
00:00:13,667 --> 00:00:17,917
The clinical studies evaluated visceral fat in that population.

5
00:00:17,917 --> 00:00:24,583
This evidence should not be converted into a general promise of weight loss or rejuvenation.

6
00:00:24,583 --> 00:00:29,667
The label explicitly says tesamorelin is not indicated for weight-loss management.

7
00:00:29,667 --> 00:00:34,750
It also states that long-term cardiovascular safety has not been established.

8
00:00:34,750 --> 00:00:39,417
Important risks include glucose intolerance, elevated IGF-1 and fluid retention.

9
00:00:39,417 --> 00:00:45,292
Product identity, patient population and outcome must stay attached when summarizing the research.